Initial multicenter experience using a novel articulating through-the-scope traction device for endoscopic submucosal dissection
Endoscopy International Open · 01.08.2023 · 11 (08) · E778-E784
DOI: 10.1055/a-2117-8444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 01.08.2023. Verfasst von Maham Hayat und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Interventional Endoscopy, AdventHealth Orlando, Orlando, United States. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and study aims A single-operator, articulating, through-the-scope (TTS) traction device was recently developed to facilitate endoscopic submucosal dissection (ESD). Clinical data on the performance of this device are limited. We report an initial multicenter experience with ESD using this articulating TTS traction device. Patients and methods Retrospective analysis on all consecutive patients who underwent ESD using this traction device (T-ESD) at five centers between August 2021 and December 2022. Endpoints included: rates of en-bloc resection, R0 resection, curative resection, and adverse events.
Results
Thirty-six patients (median age 64.8 years; 47.2% women) underwent ESD (median lesion size 40 mm; interquartile range [IRQ]: 27.5–67.5) for lesions in the esophagus (n=2), stomach (n=8), sigmoid colon (n=6), and rectum (n=20). Submucosal fibrosis was encountered in one-third of the lesions (33.3%). Median ESD time was 104.6 minutes (IQR: 65–122). En-bloc, R0 and curative resection were achieved in 94.4%, 91.6%, and 97.2%, respectively. The single patient with non-curative resection of an invasive rectal adenocarcinoma underwent surgery. There were no cases of delayed bleeding or perforation. There was no recurrence on surveillance endoscopy (n=20) at a median of 6 months (IQR: 3.75–6).
Conclusions
This initial multicenter experience demonstrates high resection rates and excellent safety profile when performing ESD with this novel articulating TTS device. Dynamic real-time traction may lower the technical difficulty of ESD. Additional studies are needed to assess its cost-effectiveness and compare its usefulness with other traction devices and techniques during ESD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Interventional Endoscopy, AdventHealth Orlando, Orlando, United States.
- Division of Gastroenterology, Hepatology & Nutrition, University of Florida, Gainesville, United States.
- Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, United States.
- Gastroenterology, Florida Center for Gastroenterology, Key Largo, United States.
- Gastroenterology, Mayo Clinic in Florida, Jacksonville, United States.
- Gastroenterology, SLU, Saint Louis, United States.
Zitieren
APA
Hayat, M., Schlachterman, A., Schiavone, G., Mizrahi, M., Park, J. K., Kumbhari, V., Cheesman, A., Draganov, P. V., Hasan, M. K., & Yang, D. (2023). Initial multicenter experience using a novel articulating through-the-scope traction device for endoscopic submucosal dissection. Endoscopy International Open, 11(08), E778-E784. https://doi.org/10.1055/a-2117-8444
Vancouver
Hayat M, Schlachterman A, Schiavone G, Mizrahi M, Park JK, Kumbhari V, et al. Initial multicenter experience using a novel articulating through-the-scope traction device for endoscopic submucosal dissection. Endoscopy International Open. 2023;11(08):E778-E784. doi:10.1055/a-2117-8444
BibTeX
@article{Hayat2023,
author = {Hayat, Maham and Schlachterman, Alexander and Schiavone, Grace and Mizrahi, Meir and Park, Jong Kyu and Kumbhari, Vivek and Cheesman, Antonio and Draganov, Peter V and Hasan, Muhammad Khalid and Yang, Dennis},
title = {Initial multicenter experience using a novel articulating through-the-scope traction device for endoscopic submucosal dissection},
journal = {Endoscopy International Open},
year = {2023},
volume = {11},
number = {08},
pages = {E778--E784},
doi = {10.1055/a-2117-8444}
}
EUVIMED